Aaron Y Mochizuki

List of Publications by Year
in descending order

27 papers	1,530 citations	1307366 7 h-index	1058333 14 g-index
28 all docs	28 docs citations	28 times ranked	2473 citing authors

#	Article	IF	Citations
1	Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Nature Medicine, 2019, 25, 477-486.	15.2	932
2	GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas. Nature, 2022, 603, 934-941.	13.7	339
3	Neoadjuvant PD-1 blockade induces T cell and cDC1 activation but fails to overcome the immunosuppressive tumor associated macrophages in recurrent glioblastoma. Nature Communications, 2021, 12, 6938.	5.8	93
4	Expression of PD-1 by T Cells in Malignant Glioma Patients Reflects Exhaustion and Activation. Clinical Cancer Research, 2019, 25, 1913-1922.	3.2	57
5	Advanced Age Increases Immunosuppression in the Brain and Decreases Immunotherapeutic Efficacy in Subjects with Glioblastoma. Clinical Cancer Research, 2020, 26, 5232-5245.	3.2	52
6	Evidence for Innate and Adaptive Immune Responses in a Cohort of Intractable Pediatric Epilepsy Surgery Patients. Frontiers in Immunology, 2019, 10, 121.	2.2	18
7	Precision Medicine in Pediatric Neurooncology: A Review. ACS Chemical Neuroscience, 2018, 9, 11-28.	1.7	12
8	Abstract CT031: GD2 CAR T cells mediate clinical activity and manageable toxicity in children and young adults with DIPG and H3K27M-mutated diffuse midline gliomas. , 2021, , .		7
9	EPCT-14. GD2 CAR T-CELLS MEDIATE CLINICAL ACTIVITY AND MANAGEABLE TOXICITY IN CHILDREN AND YOUNG ADULTS WITH H3K27M-MUTATED DIPG AND SPINAL CORD DMG. Neuro-Oncology, 2021, 23, i49-i50.	0.6	6
10	A Pilot Study of Low-Dose Craniospinal Irradiation in Patients With Newly Diagnosed Average-Risk Medulloblastoma. Frontiers in Oncology, 2021, 11, 744739.	1.3	5
11	OMIC-11. SINGLE CELL RNA SEQUENCING FROM THE CSF OF SUBJECTS WITH H3K27M+ DIPG/DMG TREATED WITH GD2 CAR T-CELLULAR THERAPY. Neuro-Oncology, 2021, 23, i39-i39.	0.6	3
12	Is Tel Hashomer camptodactyly a distinct clinical entity?. American Journal of Medical Genetics, Part A, 2015, 167, 255-258.	0.7	2
13	ATIM-12. NEOADJUVANT ANTI-PD-1 IMMUNOTHERAPY PROMOTES INTRATUMORAL AND SYSTEMIC IMMUNE RESPONSES IN RECURRENT GLIOBLASTOMA: AN IVY CONSORTIUM TRIAL. Neuro-Oncology, 2018, 20, vi3-vi3.	0.6	1
14	ATIM-25. NEOADJUVANT PD-1 ANTIBODY BLOCKADE IS ASSOCIATED WITH FOCAL UPREGULATION OF PD-L1 AND CD8 T CELL INFILTRATE IN RECURRENT GLIOBLASTOMA. Neuro-Oncology, 2018, 20, vi6-vi6.	0.6	1
15	ATIM-39. IMPROVED SURVIVAL NOTED IN GLIOBLASTOMA PATIENTS TREATED WITH ADJUVANT TLR-3 AGONIST IN SETTING OF AUTOLOGOUS LYSATE-PULSED DC VACCINATION. Neuro-Oncology, 2018, 20, vi10-vi10.	0.6	1
16	NCMP-10. AUTOIMMUNE ENCEPHALITIS IN POST-REMISSION PINEAL GERMINOMA: A CASE REPORT.. Neuro-Oncology, 2018, 20, vi195-vi196.	0.6	0
17	IMMU-21. MULTIDIMENSIONAL CHARACTERIZATION OF IMMUNE CELL POPULATIONS IN THE GLIOMA TUMOR MICROENVIRONMENT REVEALS A DOMINANT PROPORTION OF CELLS DERIVED FROM THE MYELO-MONOCYTIC LINEAGE. Neuro-Oncology, 2018, 20, vi125-vi125.	0.6	0
18	IMMU-28. HIGH-DIMENSIONAL SINGLE CELL CHARACTERIZATION OF THE SYSTEMIC INFLUENCE OF NEOADJUVANT PD-1 BLOCKADE IN PATIENTS WITH RECURRENT GLIOBLASTOMA. Neuro-Oncology, 2018, 20, vi127-vi127.	0.6	0

#	Article	IF	Citations
19	IMMU-22. SINGLE-CELL CHARACTERIZATION OF INTRATUMORAL AND SYSTEMIC IMMUNE POPULATIONS IN PEDIATRIC AND ADULT BRAIN TUMORS REVEALS DIFFERENCES IN SUBPOPULATION COMPOSITION, ACTIVATION AND MEMORY. Neuro-Oncology, 2019, 21, ii97-ii97.	0.6	0
20	ATIM-16. VALIDATION OF RESPONSE TO NEOADJUVANT ANTI-PD-1 IMMUNOTHERAPY IN RECURRENT GLIOBLASTOMA. Neuro-Oncology, 2019, 21, vi4-vi5.	0.6	0
21	IMMU-02. NEOANTIGENS ARISING FROM ALTERNATIVE SPLICING EVENTS MAY BE TARGETED BY TUMOR INFILTRATING LYMPHOCYTES IN GLIOBLASTOMAS. Neuro-Oncology, 2019, 21, vi118-vi119.	0.6	0
22	IMMU-33. IMMUNE PROFILING REVEALS INHIBITORY MACROPHAGES AND A DISTINCT SPATIAL DISTRIBUTION OF IMMUNE CELLS IN DIFFERENT TYPES OF BRAIN METASTASES. Neuro-Oncology, 2019, 21, vi126-vi126.	0.6	0
23	TMIC-06. MYELOID POPULATIONS AND THE EFFECT OF NEOADJUVANT PD-1 INHIBITION IN THE GLIOBLASTOMA MICROENVIRONMENT: A SURFACEOMIC AND TRANSCRIPTOMIC DISSECTION AT THE SINGLE-CELL LEVEL. Neuro-Oncology, 2019, 21, vi248-vi248.	0.6	0
24	MBCL-14. A STUDY OF LOW-DOSE CRANIOSPINAL RADIATION THERAPY IN PATIENTS WITH NEWLY DIAGNOSED AVERAGE-RISK MEDULLOBLASTOMA. Neuro-Oncology, 2020, 22, iii390-iii391.	0.6	0
25	Abstract PR13: Adjuvant TLR-3 administration enhances proinflammatory immune responses and is associated with extended survival in glioblastoma patients treated with dendritic cell vaccination. , 2020, , .		0
26	IMMU-41. NEOADJUVANT PD-1 BLOCKADE INDUCES T CELL AND CDC1 ACTIVATION BUT FAILS TO OVERCOME THE IMMUNOSUPPRESSIVE TUMOR ASSOCIATED MACROPHAGES IN RECURRENT GLIOBLASTOMA. Neuro-Oncology, 2021, 23, vi101-vi101.	0.6	0
27	IMMU-20. SINGLE-CELL RNASEQ OF TUMOR INFILTRATING IMMUNE CELLS FROM NEOADJUVANT ANTI-PD1 TREATED GBM PATIENTS REVEALS GLOBAL TRANSCRIPTIONAL CHANGES AND IMMUNOSUPPRESSIVE ADAPTIVE RESPONSES BY MYELOID CELLS. Neuro-Oncology, 2020, 22, ii108-ii109.	0.6	0